The broker needs shares for short sellers to borrow. They will make plenty of money on the short selling transactions.

"You sound as if you've never met a RS that you would vote for."

Absolutely correct! They have NEVER worked for me. They have ALWAYS destroyed the value of my stocks. That is plenty enough evidence for me!

Your shares will probably be used for borrowing. A.K.A. short selling. Not good! I'm telling you .... the reverse split will destroy this stock. As soon as it's done, it will be shorted back down into the pennies again.

Yes, but none of these proposals are in our best interests. Vote against all of them. You will not regret it.

I can always change my vote through proxyvote.com after the CC. But I SERIOUSLY doubt that I will. Like I said, the intent of these proposals cannot be changed by an explanation on a CC. The only thing that will change the proposals is .... actually changing the proposals!

Good luck to everybody. We will need it.

P.S. If these proposals are voted down, I'm pretty damn sure we will get a nice pop in the stock. And who knows, that may be the start of a bright future.

I was a satisfied shareholder until now. The business is doing great. It was just a matter of time before the stock would take care of itself.

But look at what they want to do now! Everything is to reduce shareholder power! Unbelievable!

* To eliminate the requirement that the Company have at least three directors (the
"Number of Directors Amendment");

* To eliminate the requirement that a nominee for director must receive at least the
vote of a majority of the Company’s outstanding shares before being elected as such
(the "Director Majority Vote Elimination Amendment");

* To reduce the quorum for shareholder meetings to one-third from one-half (the
"Quorum Reduction Amendment");

* To reduce the vote statutorily required to approve fundamental actions (such as
mergers and charter amendments) to a majority of the Company’s outstanding
shares from two–thirds (the "Fundamental Approval Reduction Amendment"); and

* To eliminate the requirement that the approval of 75% of the Company’s
outstanding shares is required for certain future charter amendments (the "Charter
Amendment Supermajority Vote Elimination Amendment").

Key words used repetitively!
ELIMINATE
ELIMINATE
REDUCE
REDUCE
ELIMINATE

So what if this is my first post? WTH difference does that make?

I got in on 2/3/2010 (so over a year now). I have added along the way. I voted NO on all proposals because there is ABSOLUTELY NOTHING anyone can say on the conference call that will change the intent of the proposals. They are not in the best interests of the shareholders. I have been through this way too many times than I care to remember.

Awesome!!! Thank you!

PLEASE, PLEASE, everyone vote AGAINST all proposals! None of them are in OUR best interests. Management is fracking nuts!

Reverse splits NEVER NEVER WORK! Especially for micro-cap penny stocks like this!

PLEASE, PLEASE, vote AGAINST all proposals!

From IR about Q4 Finanicals:


------------------------------------------------------------------
From: BioElectronics Corp IR [mailto:IR@bielcorp.com]
Sent: Tuesday, March 08, 2011 4:27 PM
To: NB
Subject: RE: Q4 Financials

Hi NB,

The audit firm we were using was dissolved. Since we switched audit firms, we have seen delays for the Q4 financials. We hope to have them soon. Please contact us if you have any other questions.

Thanks,


BioElectronics Corporation
4539 Metropolitan Court
Frederick, MD 21704
Office: (301) 874-4890
Fax: (301) 874-6935
E-mail: IR@bielcorp.com
Web: www.bielcorp.com


------------------------------------------------------------------
From: NB
Sent: Tuesday, March 08, 2011 11:26 AM
To: IR@bielcorp.com
Subject: Q4 Financials

Can you please tell me when you will be releasing your Q4 financials?

Thanks,
NB

Need audited financial statements. Then maybe this stock will move. Right now, still unbelievably pathetic. Just won't budge.

What a surprise. Back to .0001. I told everyone to be careful about this one.

Yes, shame on me for making people aware that there is no company or business anymore. Shame on me for debunking the rhetoric here that there is great news coming and people should buy this worthless company. Yes, how could I do such a horrible thing. You are absolutely right. Shame on me.

And you, of course, know this since you know when all the suckers and newbies bought and sold, right? Nice try.

When the expectation is for it to go higher on non-existent news from a non-existent company, yes, it's bogus. Typical pump and dump to sucker in newbies who don't do DD.

Notice how all the new guys here are gone now that the pump is over? Coincidence? Nuh uh!

Unfortunately we'll be seeing .0001 next week. I warned everyone here that the run to .0008 was bogus. There is no company left.

Ah ... no proof. As I expected. Thank you.

Proof please.

Awesome! Just bought more calls on that gift!

Old? Of course old. Because they are dead and can't come back to life. Therefore, can't have anything new! How can you ignore something as relevent as not being able to locate the company??

There is absolutely no info on this company anymore. It does not exist anymore. Even otcmarkets.com cannot locate the company.

I'm just saying, you need to be really careful here. This will go back to .0001 as fast as it went to .0008. Maybe not today, but probably in a week or so. I hope I'm wrong, I do own a whole lot of shares (at a huge loss), but the company is gone, so there is nothing behind this move.

Be very careful. There are people here that just want you to buy for their benefit only.

I hate to say it, but I told ya so. You really have to be careful about people pumping this stock on this board. Or any board for that matter. I'm sure they probably sold out yesterday.

http://www.otcmarkets.com/stock/NCTI/company-info

From the above link:

Investors are advised that OTC Markets Group has been unable to contact or confirm the location of this company. If you have current contact information, please complete the Update Company Information Form or send an email to info@otcmarkets.com.

http://www.otcmarkets.com/stock/NCTI/company-info

From the above link:

Investors are advised that OTC Markets Group has been unable to contact or confirm the location of this company. If you have current contact information, please complete the Update Company Information Form or send an email to info@otcmarkets.com.

Try calling the company's corporate number. Not in service.

203 226 4447

I found it here:

http://electronics.kellysearch.com/profile/nct+group,+inc./us/ct/westport/06880/900708999

Also note that their website is gone.

Try calling their number.

203 226 4447

I found it here:

http://electronics.kellysearch.com/profile/nct+group,+inc./us/ct/westport/06880/900708999

Also note that their website is gone.

Have you tried to find ANY info about the company lately? Try to call their offices.

As much as I would like to believe this move is for real .... I'm pretty sure it's not. The company does not exist anymore. There will be no news. This will be back to .0001 in about a week or so. I hope I am DEAD WRONG! But unfortunately, I don't think I am.

As much as I would like to believe this move is for real .... I'm pretty sure it's not. The company does not exist anymore. There will be no news. This will be back to .0001 in about a week or so. I hope I am DEAD WRONG! But unfortunately, I don't think I am.

I have also asked him about Dean on Facebook but did not get a reply. Unfortunately, I think they know they need to reign Dean in on his public comments.

Clinical Data, Inc. Investor Lawsuit against takeover imminent

Investigation for investors of Clinical Data, Inc. (NASDAQ:CLDA) concerning possible breaches of fiduciary duties - CLDA stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com

FOR IMMEDIATE RELEASE

PRLog (Press Release) – Feb 22, 2011 – The announcement of a proposed buyout of Clinical Data, Inc. prompted an investigation on behalf of investors in Clinical Data, Inc. (NASDAQ:CLDA) shares questioning a potential unfairness of the takeover and possible breaches of fiduciary duties by certain Clinical Data officers and directors.

If you purchased shares of Clinical Data, Inc. (NASDAQ:CLDA) prior to the announcement and continue to hold those NASDAQ: CLDA shares, you have certain options and you should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns possible breaches of fiduciary duties by certain officers and directors at Clinical Data, Inc. arising out of their attempt to sell Clinical Data to Forest Laboratories, Inc.

On Tuesdya, Feb. 22, 2011, Clinical Data, Inc. (NASDAQ: CLDA) and Forest Laboratories, Inc. (Forest) (NYSE: FRX) announced that they have entered into a merger agreement pursuant to which Forest Laboratories, Inc will acquire Clinical Data Inc for $30.00 per share in cash plus contingent consideration of up to $6.00 per share that may be paid upon achievement of certain commercial milestones related to Clinical Data’s Viibryd™.

Clinical Data said the $30.00 per share represent a 6.6% premium to the volume-weighted average trading price of CLDA stock since the first trading day after the company announced the approval of Viibryd and that it was considering a potential change of control transaction and a 19.2% premium of the closing price on that day and totals $1.2 billion on a fully diluted basis, net of net cash acquired.
But CLDA shares traded as high as $33.90 per share as recently as Feb 18 and declined in response to the takeover news to $30.96 per share, or 8.66%. In addition at least one analyst set a price target of $46 per share of Clinical Data stock.

Therefore the investigation concerns whether the Clinical Data Board of Directors undertook an adequate and fair sales process to obtain fair and maximized consideration for all shareholders of Clinical Data, Inc. (NASDAQ:CLDA) and specifically whether the Clinical Data board of directors breached their fiduciary duties to Clinical Data (CLDA) shareholder by failing to adequately shop the Company before entering into this transaction. The investigation concerns also whether Forest Laboratories, Inc is underpaying for NASDAQ CLDA shares, thus unlawfully harming CLDA stockholders.

A potential class action lawsuit would seek to maximize the amount of money and information NASDAQ:CLDA shareholders would receive in a buyout, so the law firm.

Those who purchased Clinical Data, Inc. (Public, NASDAQ:CLDA) and currently continue to hold those CLDA shares, and/or those who have any information relating the investigation, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

# # #


The Shareholders Foundation, Inc. is a professional portfolio legal monitoring service and an investor advocacy group. We do research related to shareholder issues and inform investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. At Shareholders Foundation, Inc. we are in contact with a large number of shareholders. We believe that together we can combine the interests of many investors, and use the size of our interest as leverage against the giant corporations. We offer help, support, and assistance for every shareholder. We help investors find answers to their questions and equitable solutions to their problems. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

http://www.prlog.org/11322050-clinical-data-inc-investor-lawsuit-against-takeover-imminent.html

The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Cli

NEW YORK, Feb 22, 2011 (BUSINESS WIRE) -- Levi & Korsinsky is investigating the Board of Directors of Clinical Data, Inc. ("Clinical Data" or the "Company") (Nasdaq: CLDA | PowerRating) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Forest Laboratories, Inc. ("Forest") (NYSE: FRX | PowerRating). Under the terms of the transaction, Clinical Data shareholders will receive $30.00 per share in cash, with a consideration of up to $6.00 contingent upon commercial milestones related to the drug Viibryd. The companies said the deal is valued at $1.2 billion net of an undisclosed amount of cash acquired.
Click here to learn more about the investigation: http://www.zlk.com/clinical-data-clda.html, or call: 877-363-5972.
The investigation concerns whether the Clinical Data Board of Directors breached their fiduciary duties to Clinical Data stockholders by failing to adequately shop the Company before entering into this transaction and whether Forest is underpaying for Clinical Data shares, thus unlawfully harming Clinical Data stockholders. In particular, at least one analyst set a price target of $46 per share of Clinical Data stock.
If you own common stock in Clinical Data and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/clinical-data-clda.html.
Levi & Korsinsky has expertise in prosecuting investor securities litigation and extensive experience in actions involving financial fraud and represents investors throughout the nation, concentrating its practice in securities and shareholder litigation. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major litigations involving mergers and acquisitions. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP

Levi & Korsinsky, LLP

Joseph Levi, Esq.

Eduard Korsinsky, Esq.

Tel: 212-363-7500

Toll Free: 877-363-5972

Fax: 212-363-7171

www.zlk.com

For full details on Forest Laboratories Inc (FRX) FRX. Forest Laboratories Inc (FRX) has Short Term PowerRatings at TradingMarkets. Details on Forest Laboratories Inc (FRX) Short Term PowerRatings is available at This Link.
For full details on Clinical Data Inc (CLDA) CLDA. Clinical Data Inc (CLDA) has Short Term PowerRatings at TradingMarkets. Details on Clinical Data Inc (CLDA) Short Term PowerRatings is available at This Link.

http://www.tradingmarkets.com/news/press-release/clda_frx_the-law-firm-of-levi-amp-korsinsky-llp-launches-an-investigation-into-possible-breaches-of-fiduci-1508021.html

Harwood Feffer LLP Announces Investigation of Clinical Data, Inc.

NEW YORK, Feb 22, 2011 (BUSINESS WIRE) -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Clinical Data, Inc. (NASDAQ - CLDA | PowerRating) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell CLDA to Forest Laboratories Inc. (NYSE -- FRX | PowerRating) in a transaction valued at approximately $1 billion.
Under the terms of the definitive agreement, CLDA shareholders will receive $30.00 per share and a possible additional payment of $6.00 per share of CLDA's newly approved drug Viibryd meets certain sales goals. Even with the additional $6.00 payment, the price to be paid by FRX is significantly less than analyst estimates for CLDA, one of which has been targeted at $49.00 per share. Our investigation concerns possible breaches of fiduciary duty and other violations of law related to the approval of the transaction by the Company's board of directors; in particular, whether the Company undertook a fair process to obtain fair consideration for all shareholders of CLDA.
If you own shares of CLDA and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Matthew Houston toll free at (877) 935-7400 or to sign up online, visit www.hfesq.com. You may also email Mr. Houston at mhouston@hfesq.com. For more information about class action cases in general, please visit our website: www.hfesq.com.
Harwood Feffer LLP is a national shareholder litigation firm. Harwood Feffer LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.
Attorney Advertising. (C) 2011 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
SOURCE: Harwood Feffer LLP

Harwood Feffer LLP

Matthew Houston, 877-935-7400

mhouston@hfesq.com

clowther@hfesq.com

www.hfesq.com

For full details on Forest Laboratories Inc (FRX) FRX. Forest Laboratories Inc (FRX) has Short Term PowerRatings at TradingMarkets. Details on Forest Laboratories Inc (FRX) Short Term PowerRatings is available at This Link.
For full details on Clinical Data Inc (CLDA) CLDA. Clinical Data Inc (CLDA) has Short Term PowerRatings at TradingMarkets. Details on Clinical Data Inc (CLDA) Short Term PowerRatings is available at This Link.


http://www.tradingmarkets.com/news/press-release/clda_frx_harwood-feffer-llp-announces-investigation-of-clinical-data-inc--1508030.html

Seems like it's what most CEOs and management do these days. What ever happened to the legal fiduciary responsibility to shareholders? Oh wait ... that's something for the SEC to enforce, right? Nuf said.

I have spoke to and e-mailed with Mike as well. There is NO WAY he said this. I've have asked him to clarify a number of things and he has not been able to due to SEC regulations. He says the only way he can respond, is to respond in a PR to all shareholders. He cannot answer individual specific questions or make comments about specific things to an individual investor on the phone or through e-mail. So therefore, I know what you claim is false. Everyone can believe what they want, but do not believe this. Just not true.

It's back up.

Is BIEL's site down?